Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Enzalutamide reaches STRIVE endpoints
July 2015
SHARING OPTIONS:

TOKYO & SAN FRANCISCO—The 2015 American Urology Association annual meeting saw Astellas Pharma Inc. and Medivation Inc. share data from the Phase 2 STRIVE trial, which compared enzalutamide and bicalutamide in non-metastatic (M0) and metastatic (M1) prostate cancer patients whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The trial consisted of 396 castration-resistant prostate cancer patients, 257 of whom had metastatic prostate cancer and 139 of whom presented with non-metastatic prostate cancer. Patients treated with enzalutamide saw a median progression-free survival (PFS) of 19.4 months, compared to 5.7 months in the bicalutamide arm.  Enzalutamide treatment also caused significant improvement in the secondary endpoints of radiographic PFS, time to PSA progression and PSA response rates compared to bicalutamide.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.